BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38302338)

  • 1. Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review.
    Slavkovsky R; Callen E; Pecenka C; Mvundura M
    Vaccine; 2024 Feb; 42(6):1200-1210. PubMed ID: 38302338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
    Hutubessy R; Levin A; Wang S; Morgan W; Ally M; John T; Broutet N
    BMC Med; 2012 Nov; 10():136. PubMed ID: 23146319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and operational context for national human papillomavirus (HPV) vaccine delivery in six low- and middle-income countries.
    Mvundura M; Slavkovsky R; Debellut F; Naddumba T; Bayeh A; Ndiaye C; Anena J; Vodicka E; Diop A; Gamage D; Musanabaganwa C; Tatkan G; Driwale A; Zelalem M; Badiane O; Ginige S; Hamilton E; Sibomana H; Lakew Y; Uwinkindi F; Dhufera A; Ampeire I; Kumar S; Lamontagne DS
    Vaccine; 2023 Nov; 41(49):7435-7443. PubMed ID: 37949752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
    Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
    PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia.
    Simuyemba MC; Chama-Chiliba CM; Chompolola A; Sinyangwe A; Bchir A; Asiimwe G; Chibwesha C; Masiye F
    BMC Infect Dis; 2024 Apr; 24(1):369. PubMed ID: 38565994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.
    Brennan T; Hidle A; Doshi RH; An Q; Loharikar A; Casey R; Badiane O; Ndiaye A; Diallo A; Loko Roka J; Mejia N; Abimbola T
    Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A77-A84. PubMed ID: 34955325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects.
    Botwright S; Holroyd T; Nanda S; Bloem P; Griffiths UK; Sidibe A; Hutubessy RCW
    PLoS One; 2017; 12(10):e0182663. PubMed ID: 29016596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda.
    Ngabo F; Levin A; Wang SA; Gatera M; Rugambwa C; Kayonga C; Donnen P; Lepage P; Hutubessy R
    Vaccine; 2015 Dec; 33(51):7357-7363. PubMed ID: 26519548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
    Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
    Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of human papillomavirus vaccine delivery at district and health facility levels in Zimbabwe: A school-based vaccination program targeting multiple cohorts.
    Hidle A; Brennan T; Garon J; An Q; Loharikar A; Marembo J; Manangazira P; Mejia N; Abimbola T
    Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A67-A76. PubMed ID: 35181152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M; Brisson M; Portnoy A; Hutubessy R
    Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Communication around HPV vaccination for adolescents in low- and middle-income countries: a systematic scoping overview of systematic reviews.
    Foss HS; Oldervoll A; Fretheim A; Glenton C; Lewin S
    Syst Rev; 2019 Aug; 8(1):190. PubMed ID: 31370886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost of human papillomavirus vaccination delivery at the administrative and health facility levels in the Philippines.
    Aldaba JG; Llave CL; Uy MEV; Tejano KP; Aquino MRC; Antonio P Catalig M; Sy ADR; Valverde HA; Mooney J; Slavkovsky R
    Vaccine X; 2024 Mar; 17():100459. PubMed ID: 38420134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania.
    Hsiao A; Struckmann V; Stephani V; Mmbando D; Changalucha J; Baisley K; Levin A; Morgan W; Hutubessy R; Watson-Jones D; Whitworth H; Quentin W
    Vaccine; 2023 Jan; 41(2):372-379. PubMed ID: 36460537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.
    Quentin W; Terris-Prestholt F; Changalucha J; Soteli S; Edmunds WJ; Hutubessy R; Ross DA; Kapiga S; Hayes R; Watson-Jones D
    BMC Med; 2012 Nov; 10():137. PubMed ID: 23148516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects.
    Wigle J; Coast E; Watson-Jones D
    Vaccine; 2013 Aug; 31(37):3811-7. PubMed ID: 23777956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018.
    Jit M
    Value Health; 2021 Jan; 24(1):61-66. PubMed ID: 33431154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive approach to costing cervical cancer prevention and control: a case study in the United Republic of Tanzania using the Cervical Cancer Prevention and Control Costing (C4P) tool.
    Levin A; Yuma S; Swai E; Morgan W; Gauvreau CL; Broutet N; Yeung KHT; Hutubessy R
    BMC Med; 2022 Nov; 20(1):384. PubMed ID: 36316680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.